Somewhat Positive Press Coverage Somewhat Unlikely to Impact Audentes Therapeutics (BOLD) Stock Price

News stories about Audentes Therapeutics (NASDAQ:BOLD) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Audentes Therapeutics earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.2292567009773 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of Audentes Therapeutics (NASDAQ BOLD) opened at $28.89 on Friday. Audentes Therapeutics has a 52 week low of $13.90 and a 52 week high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.88). sell-side analysts anticipate that Audentes Therapeutics will post -3.52 earnings per share for the current year.

BOLD has been the topic of several research reports. Zacks Investment Research lowered shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 17th. Bank of America reissued a “buy” rating and set a $33.00 price objective (up previously from $23.00) on shares of Audentes Therapeutics in a research note on Friday, September 22nd. Leerink Swann reissued an “outperform” rating and set a $29.00 price objective (up previously from $22.00) on shares of Audentes Therapeutics in a research note on Wednesday, November 15th. Raymond James Financial initiated coverage on shares of Audentes Therapeutics in a research note on Thursday, October 12th. They set a “market perform” rating on the stock. Finally, ValuEngine lowered shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, October 13th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $28.29.

In other news, SVP David Nagler sold 3,750 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $25.00, for a total value of $93,750.00. Following the transaction, the senior vice president now owns 3,750 shares in the company, valued at $93,750. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Louis G. Lange sold 18,000 shares of the company’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $28.32, for a total transaction of $509,760.00. Following the completion of the transaction, the director now owns 453,393 shares in the company, valued at approximately $12,840,089.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 761,500 shares of company stock worth $21,457,100. Insiders own 47.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Audentes Therapeutics (BOLD) Stock Price” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://sportsperspectives.com/2017/12/08/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-audentes-therapeutics-bold-stock-price.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Insider Buying and Selling by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply